NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
38 hedge funds and large institutions have $3.34M invested in NeuBase Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
32% more capital invested
Capital invested by funds: $2.52M → $3.34M (+$816K)
0% more funds holding
Funds holding: 38 → 38 (0)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
+$295K |
| 2 |
GBA
Garrison Bradford & Associates
New York
|
+$281K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$216K |
| 4 |
Renaissance Technologies
New York
|
+$140K |
| 5 |
VF
Virtu Financial
New York
|
+$22.7K |
Top Sellers
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$361K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$45K |
| 3 |
Goldman Sachs
New York
|
-$39K |
| 4 |
Millennium Management
New York
|
-$11K |
| 5 |
CCB
Cutter & Co Brokerage
Ballwin,
Missouri
|
-$4.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIP
26
Stoneridge Investment Partners
Radnor,
Pennsylvania
| $11K | – | – | – |
|
27
Janney Montgomery Scott
Philadelphia,
Pennsylvania
| $8K | -$819 | -3 | -10% |
|
|
JSL
28
JT Stratford LLC
Gainesville,
Georgia
| $7K | – | – | – |
|
29
State Street
Boston,
Massachusetts
| $7K | – | – | – |
|
|
WSFS
30
Wilmington Savings Fund Society
Wilmington,
Delaware
| $7K | – | – | – |
|
31
First Manhattan
New York
| $5K | – | – | – |
|
32
Morgan Stanley
New York
| $3K | -$819 | -3 | -25% |
|
|
CLOS
33
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| $3K | – | – | – |
|
|
IA
34
IFP Advisors
Tampa,
Florida
| $1K | – | – | – |
|
35
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
36
Bank of America
Charlotte,
North Carolina
| $1K | +$819 | +3 | +300% |
|
|
PCM
37
Prelude Capital Management
New York
| $1K | +$819 | +3 | New |
|
|
TRCT
38
Tower Research Capital (TRC)
New York
| – | -$45K | -177 | Closed |
|
|
39
Goldman Sachs
New York
| – | -$39K | -152 | Closed |
|
|
40
Millennium Management
New York
| – | -$11K | -44 | Closed |
|
41
Simplex Trading
Chicago,
Illinois
| – | +$819 | +3 | New |
|
NBSE Hedge Fund Activity: Q3 2017 in Review
38 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2017, worth a combined $3.34M — up 32% from $2.52M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NBSE positions and 3 closed out — a net gain of 2 holders — while 8 added to existing stakes and 6 trimmed.
The largest buyer was Wedbush Securities, opening a new position worth an estimated $295K. The largest seller was Sabby Management, cutting an estimated $361K.
- 38 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $3.34M of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2017, up 32% quarter-over-quarter.
- 5 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2017 and 3 closed out, a net change of +2 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q3 2017 was Wedbush Securities, an estimated $295K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2017 was Sabby Management, an estimated $361K sold.
Based on aggregated 13F filings for Q3 2017.